ROMAGNOLI, SIMONE
ROMAGNOLI, SIMONE
Medicina Sperimentale e Clinica
A blood drop through the pore: nanopore sequencing in hematology
2021 Bartalucci N.; Romagnoli S.; Vannucchi A.M.
Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs
2021 Balliu M.; Calabresi L.; Bartalucci N.; Romagnoli S.; Maggi L.; Manfredini R.; Lulli M.; Guglielmelli P.; Vannucchi A.M.
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera
2022 Guglielmelli, Paola; Coltro, Giacomo; Mannelli, Francesco; Rotunno, Giada; Loscocco, Giuseppe G; Mannarelli, Carmela; Maccari, Chiara; Paoli, Chiara; Romagnoli, Simone; Bartalucci, Niccolò; Vannucchi, Alessandro M
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs)
2019 Paola Guglielmelli, MD PhD, Niccolò Bartalucci, PhDBSc, Elisa Contini, PhD, Giada Rotunno, PhD, Annalisa Pacilli, PhD, Simone Romagnoli, BSc, Lara Mannelli, MD, Francesco Mannelli, MD, Giacomo Coltro, MD, Alessandro Pancrazzi, PhD, Valentina Ariu, BSci, Sara Fiaccabrino, Roberto Semeraro, Alberto Magi, PhD, Carmela Mannarelli, PhD, Francesca Gesullo, BSci, Chiara Paoli, PhD, Alessandro M. Vannucchi, MD
Long Reads, Short Time: Feasibility of Prenatal Sample Karyotyping by Nanopore Genome Sequencing
2019 Bartalucci, Niccolò; Romagnoli, Simone; Contini, Elisa; Marseglia, Giuseppina; Magi, Alberto; Guglielmelli, Paola; Pelo, Elisabetta; Vannucchi, Alessandro M
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis
2022 Guglielmelli P, Irushani Vanderwert F, Romagnoli S, Coltro G, Loscocco GG, Mannelli F, Calabresi L, Gentili G, Rotunno G, Bartalucci N, Boldrini V, Sant'Antonio E, Tarantino D, Pieraccioli M, Vannucchi AM
Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2
2021 Romagnoli S.; Bartalucci N.; Gesullo F.; Balliu M.; Bonifacio S.; Fernandez A.G.L.; Mannelli F.; Bolognini D.; Pelo E.; Mecucci C.; Guglielmelli P.; Vannucchi A.M.
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features
2020 Coltro G.; Rotunno G.; Mannelli L.; Mannarelli C.; Fiaccabrino S.; Romagnoli S.; Bartalucci N.; Ravenda E.; Gelli E.; Sant'Antonio E.; Patnaik M.M.; Tefferi A.; Vannucchi A.M.; Guglielmelli P.
Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer
2019 Bacci M.; Lorito N.; Ippolito L.; Ramazzotti M.; Luti S.; Romagnoli S.; Parri M.; Bianchini F.; Cappellesso F.; Virga F.; Gao Q.; Simoes B.M.; Marangoni E.; Martin L.-A.; Comito G.; Ferracin M.; Giannoni E.; Mazzone M.; Chiarugi P.; Morandi A.
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates
2022 Loscocco, Giuseppe G; Guglielmelli, Paola; Mannelli, Francesco; Mora, Barbara; Mannarelli, Carmela; Rotunno, Giada; Pancani, Fabiana; Maccari, Chiara; Bartalucci, Niccolò; Romagnoli, Simone; Coltro, Giacomo; Passamonti, Francesco; Vannucchi, Alessandro M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A blood drop through the pore: nanopore sequencing in hematology | 2021 | Bartalucci N.; Romagnoli S.; Vannucchi A.M. | |
| Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs | 2021 | Balliu M.; Calabresi L.; Bartalucci N.; Romagnoli S.; Maggi L.; Manfredini R.; Lulli M.; Guglielmelli P.; Vannucchi A.M. | |
| ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera | 2022 | Guglielmelli, Paola; Coltro, Giacomo; Mannelli, Francesco; Rotunno, Giada; Loscocco, Giuseppe G; Mannarelli, Carmela; Maccari, Chiara; Paoli, Chiara; Romagnoli, Simone; Bartalucci, Niccolò; Vannucchi, Alessandro M | |
| Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) | 2019 | Paola Guglielmelli, MD PhD, Niccolò Bartalucci, PhDBSc, Elisa Contini, PhD, Giada Rotunno, PhD, Annalisa Pacilli, PhD, Simone Romagnoli, BSc, Lara Mannelli, MD, Francesco Mannelli, MD, Giacomo Coltro, MD, Alessandro Pancrazzi, PhD, Valentina Ariu, BSci, Sara Fiaccabrino, Roberto Semeraro, Alberto Magi, PhD, Carmela Mannarelli, PhD, Francesca Gesullo, BSci, Chiara Paoli, PhD, Alessandro M. Vannucchi, MD | |
| Long Reads, Short Time: Feasibility of Prenatal Sample Karyotyping by Nanopore Genome Sequencing | 2019 | Bartalucci, Niccolò; Romagnoli, Simone; Contini, Elisa; Marseglia, Giuseppina; Magi, Alberto; Guglielmelli, Paola; Pelo, Elisabetta; Vannucchi, Alessandro M | |
| Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis | 2022 | Guglielmelli P, Irushani Vanderwert F, Romagnoli S, Coltro G, Loscocco GG, Mannelli F, Calabresi L, Gentili G, Rotunno G, Bartalucci N, Boldrini V, Sant'Antonio E, Tarantino D, Pieraccioli M, Vannucchi AM | |
| Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2 | 2021 | Romagnoli S.; Bartalucci N.; Gesullo F.; Balliu M.; Bonifacio S.; Fernandez A.G.L.; Mannelli F.; Bolognini D.; Pelo E.; Mecucci C.; Guglielmelli P.; Vannucchi A.M. | |
| RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features | 2020 | Coltro G.; Rotunno G.; Mannelli L.; Mannarelli C.; Fiaccabrino S.; Romagnoli S.; Bartalucci N.; Ravenda E.; Gelli E.; Sant'Antonio E.; Patnaik M.M.; Tefferi A.; Vannucchi A.M.; Guglielmelli P. | |
| Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer | 2019 | Bacci M.; Lorito N.; Ippolito L.; Ramazzotti M.; Luti S.; Romagnoli S.; Parri M.; Bianchini F.; Cappellesso F.; Virga F.; Gao Q.; Simoes B.M.; Marangoni E.; Martin L.-A.; Comito G.; Ferracin M.; Giannoni E.; Mazzone M.; Chiarugi P.; Morandi A. | |
| SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates | 2022 | Loscocco, Giuseppe G; Guglielmelli, Paola; Mannelli, Francesco; Mora, Barbara; Mannarelli, Carmela; Rotunno, Giada; Pancani, Fabiana; Maccari, Chiara; Bartalucci, Niccolò; Romagnoli, Simone; Coltro, Giacomo; Passamonti, Francesco; Vannucchi, Alessandro M |